Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
- Wound Care
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 29009
An implantable human heart valve treated with growth factor effective on fibroblast cells and populated with fibroblast cells in an amount and for a time period effective for rendering the heart valve substantially non-immunogenic upon implant into a mammal. An implantable non-human mammalian heart valve treated with growth factor effective on fibroblast cells and populated with fibroblast cells in an amount and for a time period effective for rendering the heart valve substantially non-immunogenic upon implant into a mammal.
IPSCIO Record ID: 5464
Orton Patents include, but are not limited to, U.S. Patent Nos. 5,192,312; 5,772,695; 5,863,296; 5,855,617, and U.S. Provisional Application Serial No. 60/219,548 as well as corresponding Non-Provisional Application Serial No. 09/909914 and PCT Application Serial No. PCT/US01/22018.
Goldstein Patents shall mean U.S. Patent Nos. 5,613,982; 5,632,778; 5,843,182; 5,899,936; and all pending and future applications and patents, both U.S. and foreign, arising from these patents, as well as any continuations, continued prosecution applications, continuations-in-part, divisions, or substitutions thereof.
Tissue Decellularization Patent Applications shall mean U.S. Application Serial Nos. 08/838,852 and 09/735,522 and all pending and future applications.
Tissue Graft Patent Applications shall mean U.S. Application Serial Nos. 60/178,632 and 09/769,769 and all pending and future applications and patents.
Unstented Heart Valve Patent Applications shall mean U.S. Application Serial No. 09/540,525 and all pending and future applications and patents, both U.S. and foreign, arising from these patents, as well as any continuations, continued prosecution applications, continuations-in-part, divisions, or substitutions thereof.
IPSCIO Record ID: 266751
Licensor also grants a non-exclusive license to Know-how, and a non-exclusive license to use Biological Materials in connection with licensees research and development of Licensed Products.
Biological Materials shall mean the specific proprietary biological materials, including Progeny and Unmodified Derivatives of those materials. Progeny shall mean an unmodified descendant from the material, such as a virus from virus, cell from a cell, or organism from an organism; Unmodified Derivatives shall mean substances created by the Licensee which constitute an unmodified functional subunit or product expressed by the original material, such as subclones of unmodified cell lines, purified or fractionated subsets of the original material, proteins expressed by DNA/RNA, or monoclonal antibodies secreted by a hybridoma cell line; and Modifications shall mean substances created by the Licensee which contain or incorporate the material.
IPSCIO Record ID: 294016
IPSCIO Record ID: 257470
The Licensee acknowledges that the rights granted by it to Sublicensee pursuant to the Collaboration Agreement in respect of what is defined thereunder as the Second Product, the Licensee hereby declaring that what is defined as the First Product thereunder has never been and never will be developed, include the grant of rights to use Licensors rights in the Licensed Information and/or the Joint Patents.
The original agreement is non-exclusive.
The sublicense collaboration is for FGF or fibroblast growth factor variant.
The fibroblast growth factors are a family of cell signalling proteins that are involved in a wide variety of processes, most notably as crucial elements for normal development.
The Licensee focuses on modulating the fibroblast growth factor system to enable it to create solutions for tissue regeneration.
IPSCIO Record ID: 372627
Licensor grants an exclusive worldwide license under the Licensed Technology to use, offer to sell, sell, and otherwise commercialize, solely in the Field of Use and the Field of Extended Use, Licensed Products which include rhPDGF-BB purchased from Licensor.
For the Sublicenses, Licensor grants the right to grant sublicenses under the Licensed Technology to Distributors to use, offer to sell and sell, in the Field of Use and the Field of Extended Use, Licensed Products purchased from Licensor.
Proven rhPDGF technology is FDA approval of GEM 21S for periodontal bone regeneration suggests potential for efficacy in other bone and musculoskeletal applications.
GEM 21SÂ® growth-factor enhanced matrix is indicated to treat the following periodontally related defects intrabony periodontal defects; furcation periodontal defects; and gingival recession associated with periodontal defects.
GEM 21SÂ® growth-factor enhanced matrix combines a bioactive protein â€“ highly purified rhPDGF-BB â€“ with an osteoconductive matrix, ÃŸ-TCP.
GEM 21SÂ® is the only dental therapy containing rhPDGF-BB, one of the main growth factors found in the human body and well known for its stimulatory role in wound healing.
This completely synthetic grafting system is engineered to stimulate wound healing and bone regeneration when implanted in the body by triggering a cascade of molecular events that continues on even after the implanted rhPDGF-BB is gone.
The Field of Use means all uses related to the treatment, cure, or relief of mammals for periodontal diseases and/or the repair, restoration or reconstruction of oral and cranioâ€¢ maxillofacial osseous defects.
The Field of Extended Use shall mean all uses outside the Field of Use that are related to the treatment and healing of bone, cartilage, tendon and ligaments of the skeletal tissue system in animals, excluding humans, excluding the treatment and healing of soft tissue wounds.
IPSCIO Record ID: 120969
NOVAGOLD is a pre-filled hydrogel textured single lumen breast implant that utilizes a unique water based filling material that is designed to be biocompatible.
The Licensee Patents and applications relate to alternative fill material, textured shell surface, water vapor barrier shell, biocompatible catheter and saline implant with single valve.